Back to Vector Core
Retrovirus providing stable integration in both dividing and nondividing cells, used for the production of permanent cell lines and long-term modifications for in vivo and ex vivo applications.
Standard turn-around time is 2 weeks unless otherwise noted.
| Service | Yield/Amount | Internal Price* | External Price |
| Lentiviral shRNA tester samples (5 × 3 ml of supernatant) | Tester samples are a “quick and dirty” product tailored toward screening several shRNA products. Each 3 ml tester prep requires 2.5 μg of purified proviral plasmid DNA. The cost is for a set of five. However, if you do not have 5 constructs, multiple 3 ml preps of the same construct can be performed (2 of one construct and 3 of another, etc.). | $309.00 | $463.50 |
| Concentrated Lentiviral/Retroviral Production (small scale, VSVG) | 100 mls of supernatant concentrated to 10 mls of 10X (or as requested) in DMEM (or as requested); 80 μg of proviral plasmid required. | $678.00 | $1,017.00 |
| Concentrated Lentiviral/Retroviral Production (large scale, VSVG) | 1 liter of supernatant concentrated to 80 mls of 10X (or as requested) in DMEM (or as requested); 650 μg of proviral plasmid required. | $1,627.00 | $2,440.50 |
| Concentrated Lentiviral/Retroviral Stock (10 ml at 10X concentration) | Pre-made stocks of popular viral vectors at 1E+07 TU/ml (pLL3.7dsRED, pLLEV GFP, pGipZ Scrambled). Each sample is 10 mls of 10X concentrated virus in DMEM. | $366.00 | $549.00 |
| Lentiviral/Retroviral Titer with Fluorescence 200 μl of virus is required. | 1-2 weeks | $369.00 | $553.50 |
| Lentiviral/Retroviral Titer with Antibiotic Selection 200 μl of virus is required. | 2-3 weeks | $417.00 | $625.50 |
| Lentiviral/Retroviral Transduction | Transduction of lentiviral constructs onto cells provided by the customer, or on A549 lung carcinoma cells provided by the Vector Core. | $310.00 | $465.00 |
| Name | Species | Description |
| Lenti GFP-luciferase | rHIV | pLentilox vector containing dual expression cassettes in which CAG promoter drives dscGFP-2A-firefly luciferase and EFc promoter expressing puromycin. |
| Lenti-GFP | rHIV | Reporter vector that allows experimental model infection conditions to be optimized through a GFP marker. Expression is driven from a CMV promoter. The proviral plasmid is pLLEV-GFP. |
| Lenti-pGipZ scrambled control | rHIV | Model control for pGipZ constructs containing an shRNAmir. The construct has a CMV promoter with GFP-IRES-Puro-shRNAmir expression cassette. The proviral plasmid is pGipZ scrambled control (non-silencing). The non-silencing shRNAmir sequence is expressed under the control of the CMV promoter and contains no homology to known mammalian genes. |
| Lenti 3.7 dsRED | rHIV | Model control for pLL3.7 dsRed in which U6 promoter (empty) was used to drive expression of shRNA. The dsRed marker contained in the vector is expressed through a separate CMV promoter downstream of the U6-siRNA expression cassette. The proviral plasmid is pLL 3.7-dsRED. |
Viewable files of maps and sequences for each type.
| Name | Species | Description |
| pLentilox GFP-luciferase | rHIV | pLentilox vector containing dual expression cassettes in which CAG promoter drives dscGFP-2A-firefly luciferase and EFc promoter expressing puromycin. |
| pLentilox 3.7 GFP | rHIV | Proviral plasmid used in shRNA construction in which shRNA expression is driven through a U6 promoter. GFP marker contained in the vector is expressed through a separate CMV promoter downstream of the U6-siRNA expression cassette. This allows simultaneous expression of both shRNA and fluorescent marker. GFP is co-integrated into host cell genome with shRNA which allows for convenient tracking of viral uptake in the cell and selection through fluorescent visualization. |
| pLentilox 3.7 dsRed | rHIV | Proviral plasmid used in shRNA construction in which shRNA expression is driven through a U6 promoter. The dsRed marker contained in the vector is expressed through a separate CMV promoter downstream of the U6-siRNA expression cassette. This allows simultaneous expression of both shRNA and selectable marker. dsRed is co-integrated into host cell genome with shRNA which allows for convenient tracking of viral uptake in the cell and selection through fluorescent visualization. |
| pLentilox 3.7 Puro | rHIV | Pro-viral plasmid used in shRNA construction containing a puromycin selectable marker. U6 promoter is upstream of CMV-Puromycin expression cassette for simultaneous production of shRNA and selectable marker. Puromycin co-integrates into host cells genome which allows for convenient, stable selection. |
| pLentilox RSV GFP | rHIV | Transgene expression of this proviral plasmid is driven by an RSV promoter. Vector also contains separate expression cassette for GFP marker utilizing a CMV promoter. GFP is co-integrated into host cell genome and allows for convenient tracking of viral uptake in the cell and selection through fluorescent visualization. |
| pLentilox RSV2dsRed | rHIV | Transgene expression of this proviral plasmid is driven by an RSV promoter. Vector also contains separate expression cassette for dsRed marker utilizing a CMV promoter. dsRed is co-integrated into host cell genome and allows for convenient tracking of viral uptake in the cell and selection through fluorescent visualization. |
| pLentilox RSV puro | rHIV | Transgene expression of this pro-viral plasmid is driven by an RSV promoter. Vector also contains separate expression cassette for puro marker utilizing a CMV promoter. Puro is co-integrated into host cell genome and allows for convenient tracking of viral uptake in the cell and puromycin selection. |
| pLentilox IRES GFP | rHIV | Proviral plasmid containing a bicistronic element to express both a transgene and GFP marker driven by one CMV promoter through the use of an IRES element. IRES elements tend not to be as strong as typical promoter expression cassettes and therefore could result in a weaker GFP signal. |
| pLentilox IRES Puro | rHIV | Proviral plasmid containing a bicistronic element to express both a transgene and a puromycin selectable marker driven by one CMV promoter through the use of an IRES element. IRES elements tend not to be as strong as typical promoter expression cassettes and therefore could result in a weaker puromycin response. |
| pLentilox EV | rHIV | Proviral plasmid in which transgene expression is driven by a CMV promoter. Vector contains no selectable marker. The use of the CMV promoter is ideal for transgene over-expression in a wide range of cell types. |
| pLenti6/V5-DEST | rHIV | This Invitrogen expression system utilizes the Gateway Technology of gene transfer. This vector is ideal for multiple expression systems. Contains blasticidin resistance gene for stable selection. This plasmid is fully compatible with Vector Core system for custom lentivirus production. |
| pLenti6/V5-GW/LacZ | rHIV | This Invitrogen expression system utilizes the Gateway Technology of gene transfer. This vector allows simple subcloning of transgene. Blasticidin resistance gene for stable selection. This plasmid is fully compatible with Vector Core system for custom lentivirus production. |
| pLentilox EV-GFP | rHIV | Proviral plasmid in which transgene expression is driven by a CMV promoter. Vector contains the GFP marker. The use of the CMV promoter is ideal for transgene over-expression in a wide range of cell types. |
| pLentilox EV-Luc | rHIV | Proviral plasmid in which transgene expression is driven by a CMV promoter. Vector contains the luciferase (firefly) marker. The use of the CMV promoter is ideal for transgene over-expression in a wide range of cell types. |
| Lenti-FIV-GFP | rFIV | Recombinant Feline Immunodeficiency Virus (FIV) reporter vector expressing the GFP marker. Expression is driven from an RSV promoter. |
| Lenti-FIV-LacZ | rFIV | Recombinant Feline Immunodeficiency Virus (FIV) reporter vector expressing the β-gal marker. Expression is driven from an RSV promoter. |
Please see our shRNA page for details.
Room C552
Medical Science Research Building (MSRB) II
1150 West Medical Center Drive
Ann Arbor, MI 48109
1150 West Medical Center Drive
Ann Arbor, MI 48109
Phone:: 734-615-1332
Email: [email protected]
The Vector Core is one of the Biomedical Research Core Facilities, and a part of the Medical School Office of Research, where our mission is to foster an environment of innovation and efficiency that serves the Michigan Medicine research community and supports biomedical science from insight to impact.
